



27 Birchwood
Avenue
London
N10 3BE

T +44 (0) 208 365 2185
m +44 (0) 7818012891
info@phmrconsulting.com
www.phmrconsulting.com

Directors

Mark Ratcliffe
BSc MSc PhD
Peter Hudson
BSc MSc

SCHIZOPHRENIA

Economic/ health outcome publication alerts added in

January 2008

Searches found 48 articles that met criteria: 8 are commercially significant of which
4 are business and scientific critical and are reviewed

Papers reviewed this month:

Kilzieh N, Todd-Stenberg JA, Kennedy A, Wood AE, Tapp AM. Time to Discontinuation and Self-Discontinuation of Olanzapine and Risperidone in Patients With Schizophrenia in a Naturalistic Outpatient Setting. *J Clin Psychopharmacol.* 2008 Feb;28(1):74-77.

Bigos KL, Pollock BG, Coley KC, Miller del D, Marder SR, Aravagiri M, Kirshner MA, Schneider LS, Bies RR. Sex, race, and smoking impact olanzapine exposure. *J Clin Pharmacol.* 2008 Feb; 48(2):157-65.

Swartz MS, Wagner HR, Swanson JW, Stroup TS, McEvoy JP, Reimherr F, Miller DD, McGee M, Khan A, Canive JM, Davis SM, Hsiao JK, Lieberman JA; for the CATIE Investigators. The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: Results from the CATIE study. *Schizophr Res.* 2008 Jan 10; [Epub ahead of print]

Davies LM, Barnes TR, Jones PB, Lewis S, Gaughran F, Hayhurst K, Markwick A, Lloyd H; the CUTLASS Team. A Randomized Controlled Trial of the Cost-Utility of Second-Generation Antipsychotics in People with Psychosis and Eligible for Clozapine. *Value Health.* 2007 Dec 18; [Epub ahead of print]

phmr consulting ltd.
Registered in England
Number 6551482
Registered office
Melville House
8-12 Woodhouse
Road
London N12 ORG